Nishii Ryuichi, Volgin Andrei Y, Mawlawi Osama, Mukhopadhyay Uday, Pal Ashutosh, Bornmann William, Gelovani Juri G, Alauddin Mian M
Department of Experimental Diagnostic Imaging, M. D. Anderson Cancer Center, The University of Texas, Box 059, T8.3895, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Eur J Nucl Med Mol Imaging. 2008 May;35(5):990-8. doi: 10.1007/s00259-007-0649-1. Epub 2007 Dec 4.
Clevudine (L: -FMAU) an un-natural analogue of thymidine, is in clinical trials for the treatment of hepatitis B virus (HBV). L: -FMAU is phosphorylated by cellular kinases such as thymidine kinase 1 and deoxycytidine kinase, and its triphosphate form inhibits HBV deoxyribonucleic acid synthesis. Thus, L: -FMAU, radiolabeled with an appropriate isotope, may be useful for positron emission tomography (PET) imaging of tumor proliferation. We evaluated [18F]-L-FMAU as a PET imaging agent in tumor-bearing mice and compared the results with those of two other radiotracers, [18F]-d-FMAU and [18F]-FLT.
Subcutaneous xenografts of the human lung cancer cell lines H441 and H3255 were established in mice. A micro-PET scanner was used to obtain images of the tumor-bearing animals with [18F]-L-FMAU, [18F]-D-FMAU, and [18F]-FLT.
At 2 h postinjection, the tumor uptake (% ID/g) of 18F]-L: -FMAU, 18F]-D: -FMAU, and [18F]-FLT in the faster-growing H441 cells was 3.13 +/- 1.11, 7.74 +/- 1.39, and 5.10 +/- 1.45, respectively. The corresponding values for the slower-growing H3255 cells were 1.38 +/- 0.81, 4.49 +/- 1.08, and 0.57 +/- 0.33. Tumor/muscle ratios of accumulation for [18F]-L: -FMAU, [18F]-D: -FMAU, and [18F]-FLT in H441 cells were 4.15 +/- 1.82, 3.37 +/- 1.19, and 12.94 +/- 4.38, respectively, and the corresponding values in H3255 cells were 1.62 +/- 0.50, 1.96 +/- 0.74, and 1.50 +/- 0.90.
[18F]-L: -FMAU may be a useful agent for imaging tumor proliferation in fast-growing human lung cancers by PET.
克来夫定(L:-FMAU)是胸苷的非天然类似物,正在进行治疗乙型肝炎病毒(HBV)的临床试验。L:-FMAU 可被细胞激酶如胸苷激酶 1 和脱氧胞苷激酶磷酸化,其三磷酸形式可抑制 HBV 脱氧核糖核酸合成。因此,用适当同位素进行放射性标记的 L:-FMAU 可能有助于肿瘤增殖的正电子发射断层扫描(PET)成像。我们评估了[18F]-L-FMAU 作为荷瘤小鼠 PET 成像剂,并将结果与其他两种放射性示踪剂[18F]-d-FMAU 和[18F]-FLT 的结果进行比较。
在小鼠体内建立人肺癌细胞系 H441 和 H3255 的皮下异种移植瘤。使用微型 PET 扫描仪获取荷瘤动物注射[18F]-L-FMAU、[18F]-D-FMAU 和[18F]-FLT 后的图像。
注射后 2 小时,生长较快的 H441 细胞中[18F]-L:-FMAU、[18F]-D:-FMAU 和[18F]-FLT 的肿瘤摄取率(%ID/g)分别为 3.13±1.11、7.74±1.39 和 5.10±1.45。生长较慢的 H3255 细胞的相应值分别为 1.38±0.81、4.49±1.08 和 0.57±0.33。H441 细胞中[18F]-L:-FMAU、[18F]-D:-FMAU 和[18F]-FLT 的肿瘤/肌肉摄取比值分别为 4.15±1.82、3.37±1.19 和 12.94±4.38,H3255 细胞中的相应值分别为 1.62±0.50、1.96±0.74 和 1.50±0.90。
[18F]-L:-FMAU 可能是通过 PET 对快速生长的人肺癌肿瘤增殖进行成像的有用试剂。